Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2020

11.02.2020 | Original Article

Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution

verfasst von: Toshio Takagi, Kazuhiko Yoshida, Arisa Wada, Tsunenori Kondo, Hironori Fukuda, Hiroki Ishihara, Hirohito Kobayashi, Junpei Iizuka, Masayoshi Okumi, Hideki Ishida, Yoji Nagashima, Kazunari Tanabe

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

Identifying the predictive factors for tumor recurrence after partial nephrectomy (PN) is useful to determine patients who require careful observation after surgery. Therefore, we investigated recurrence after partial nephrectomy (PN) in patients with clinical T1 renal cell carcinoma (RCC) and analyzed predictive factors for recurrence-free survival (RFS).

Methods

This study included 1227 patients who underwent PN for clinical T1 RCC and retrospectively investigated patients’ characteristics and tumor factors that are associated with tumor recurrence.

Results

The median patient age was 59 years, and the median tumor size was 30 mm. Although 970 (74%) and 319 (26%) patients had clinical T1a and T1b RCCs, respectively, 20 patients (1.6%) were upstaged to pathological T3a. A positive surgical margin was found in 19 (1.5%) patients. The distribution of surgical approaches was open surgery in 428 (35%) patients and minimally invasive surgery in 799 (65%) patients. With a median follow-up of 35 months (Interquartile range 19–55 months), 39 (3.2%) patients, including ten with local recurrence, five with recurrence in the ipsilateral kidney, and 28 with other organs or lymph-nude, developed recurrence. The 3-year RFS was 99%, and the median recurrence time from PN was 19 months (interquartile range: 11–37 months). Multivariate analysis identified high grade tumor and upstaging to pT3a as significant predictors for worse RFS.

Conclusion

Patients with high grade tumors and tumors upstaged to pT3 had a high risk of worse RFS, which suggested that careful monitoring is required for such patients after PN, even if a good prognosis is achieved in patients with clinical T1 RCC.
Literatur
1.
Zurück zum Zitat Mouracade P, Kara O, Maurice MJ et al (2017) Patterns and predictors of recurrence after partial nephrectomy for kidney tumors. J Urol 197:1403–1409CrossRef Mouracade P, Kara O, Maurice MJ et al (2017) Patterns and predictors of recurrence after partial nephrectomy for kidney tumors. J Urol 197:1403–1409CrossRef
2.
Zurück zum Zitat Shah PH, Moreira DM, Okhunov Z et al (2016) Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. J Urol 196:327–334CrossRef Shah PH, Moreira DM, Okhunov Z et al (2016) Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. J Urol 196:327–334CrossRef
3.
Zurück zum Zitat Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s changed: communication from the International Union against Cancer and the American Joint Committee on Cancer. Cancer 116:5336–5339CrossRef Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s changed: communication from the International Union against Cancer and the American Joint Committee on Cancer. Cancer 116:5336–5339CrossRef
4.
Zurück zum Zitat Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70:93–105CrossRef Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70:93–105CrossRef
5.
Zurück zum Zitat Lane BR, Campbell SC, Gill IS (2013) 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol 190:44–49CrossRef Lane BR, Campbell SC, Gill IS (2013) 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol 190:44–49CrossRef
6.
Zurück zum Zitat Mouracade P, Kara O, Dagenais J et al (2017) Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors. World J Urol 35:1425–1433CrossRef Mouracade P, Kara O, Dagenais J et al (2017) Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors. World J Urol 35:1425–1433CrossRef
7.
Zurück zum Zitat Jeong SH, Kim JK, Park J et al (2016) Pathological T3a upstaging of clinical T1 renal cell carcinoma: outcomes according to surgical technique and predictors of upstaging. PLoS ONE 11:e0166183CrossRef Jeong SH, Kim JK, Park J et al (2016) Pathological T3a upstaging of clinical T1 renal cell carcinoma: outcomes according to surgical technique and predictors of upstaging. PLoS ONE 11:e0166183CrossRef
8.
Zurück zum Zitat Shah PH, Moreira DM, Patel VR et al (2017) partial nephrectomy is associated with higher risk of relapse compared with radical nephrectomy for clinical stage T1 renal cell carcinoma pathologically up staged to T3a. J Urol 198:289–296CrossRef Shah PH, Moreira DM, Patel VR et al (2017) partial nephrectomy is associated with higher risk of relapse compared with radical nephrectomy for clinical stage T1 renal cell carcinoma pathologically up staged to T3a. J Urol 198:289–296CrossRef
9.
Zurück zum Zitat Shum CF, Bahler CD, Sundaram CP (2018) Impact of positive surgical margins on overall survival after partial nephrectomy-a matched comparison based on the national cancer database. Urol Oncol 36:90.e15–90.e21CrossRef Shum CF, Bahler CD, Sundaram CP (2018) Impact of positive surgical margins on overall survival after partial nephrectomy-a matched comparison based on the national cancer database. Urol Oncol 36:90.e15–90.e21CrossRef
10.
Zurück zum Zitat Qi N, Li T, Ning X et al (2017) Clinicopathologic features and prognosis of sporadic bilateral renal cell carcinoma: a series of 148 cases. Clin Genitourin Cancer 15:618–624CrossRef Qi N, Li T, Ning X et al (2017) Clinicopathologic features and prognosis of sporadic bilateral renal cell carcinoma: a series of 148 cases. Clin Genitourin Cancer 15:618–624CrossRef
Metadaten
Titel
Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution
verfasst von
Toshio Takagi
Kazuhiko Yoshida
Arisa Wada
Tsunenori Kondo
Hironori Fukuda
Hiroki Ishihara
Hirohito Kobayashi
Junpei Iizuka
Masayoshi Okumi
Hideki Ishida
Yoji Nagashima
Kazunari Tanabe
Publikationsdatum
11.02.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01632-x

Weitere Artikel der Ausgabe 5/2020

International Journal of Clinical Oncology 5/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.